DE60121567D1 - Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung - Google Patents

Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung

Info

Publication number
DE60121567D1
DE60121567D1 DE60121567T DE60121567T DE60121567D1 DE 60121567 D1 DE60121567 D1 DE 60121567D1 DE 60121567 T DE60121567 T DE 60121567T DE 60121567 T DE60121567 T DE 60121567T DE 60121567 D1 DE60121567 D1 DE 60121567D1
Authority
DE
Germany
Prior art keywords
promoterregion
polymorphisms
diagnostic
cyp2d6 gene
therapeutic uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121567T
Other languages
English (en)
Other versions
DE60121567T2 (de
Inventor
Sebastian Raimundo
Ulrich Zanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epidauros Biotechnologie AG
Original Assignee
Epidauros Biotechnologie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie AG filed Critical Epidauros Biotechnologie AG
Publication of DE60121567D1 publication Critical patent/DE60121567D1/de
Application granted granted Critical
Publication of DE60121567T2 publication Critical patent/DE60121567T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60121567T 2000-01-31 2001-01-30 Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung Expired - Lifetime DE60121567T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00101889 2000-01-31
EP00101889 2000-01-31
PCT/EP2001/000954 WO2001055432A2 (en) 2000-01-31 2001-01-30 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications

Publications (2)

Publication Number Publication Date
DE60121567D1 true DE60121567D1 (de) 2006-08-31
DE60121567T2 DE60121567T2 (de) 2007-07-05

Family

ID=8167736

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121567T Expired - Lifetime DE60121567T2 (de) 2000-01-31 2001-01-30 Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung

Country Status (9)

Country Link
US (2) US8129112B2 (de)
EP (1) EP1276880B1 (de)
JP (1) JP2004506405A (de)
AT (1) ATE333504T1 (de)
AU (1) AU2001257913A1 (de)
CA (1) CA2398104C (de)
DE (1) DE60121567T2 (de)
ES (1) ES2267787T3 (de)
WO (1) WO2001055432A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021286D0 (en) * 2000-08-30 2000-10-18 Gemini Genomics Ab Identification of drug metabolic capacity
JP2008504826A (ja) * 2004-06-30 2008-02-21 ティーエム バイオサイエンス ピージーエクス インコーポレイティッド チトクロムｐ４５０−２ｄ６をコードする遺伝子における変異を検出する方法
GB0614396D0 (en) * 2006-07-20 2006-08-30 Knox Geoffrey M Test for the presence of active CYP450 2D6
CN114317533B (zh) * 2022-01-12 2023-08-29 武汉艾迪康医学检验所有限公司 一组探针和利用杂交捕获法检测药物基因组学相关基因cyp2d6多态性的建库试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0730663B1 (de) * 1993-10-26 2003-09-24 Affymetrix, Inc. Felder von nukleinsaeuresonden auf biologischen chips
WO2001096604A2 (en) 2000-06-12 2001-12-20 Genicon Sciences Corporation Assay for genetic polymorphisms using scattered light detectable labels

Also Published As

Publication number Publication date
EP1276880B1 (de) 2006-07-19
WO2001055432A3 (en) 2002-10-31
US20120270948A1 (en) 2012-10-25
ATE333504T1 (de) 2006-08-15
CA2398104C (en) 2015-03-10
AU2001257913A1 (en) 2001-08-07
DE60121567T2 (de) 2007-07-05
JP2004506405A (ja) 2004-03-04
EP1276880A2 (de) 2003-01-22
US20040224424A1 (en) 2004-11-11
WO2001055432A2 (en) 2001-08-02
CA2398104A1 (en) 2001-08-02
ES2267787T3 (es) 2007-03-16
US8129112B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
ATE532860T1 (de) B7-ähnliche moleküle und deren anwendungen
EP2154157A3 (de) Varianten der Fc Region
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
CY1116527T1 (el) Μεταλλαγματα της πρωτεϊνης νουκλεοφοσμινη (νρμ), αντιστοιχες γονιδιακες αλληλουχιες και χρησεις αυτων
WO2004041212A3 (en) Apkc isoforms in nervous system disorders and cancer
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DE60121567D1 (de) Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung
WO2006003520A3 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
CY1107437T1 (el) Νεα πολυπεπτιδια kcnq και οι χρησεις τους στη διαγνωση διανοητικων διαταραχων
DE60037126D1 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
ATE328077T1 (de) Gen assoziiert mit iga glomerulonephritis
DE602005013080D1 (de) Für prkcb1 kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
ATE431855T1 (de) Menschliches autismus-suszeptibilitätsgen und verwendungen davon
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
WO2003038130A8 (en) Therapeutics and diagnostics for disorders of erythropoiesis
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
WO2006090288A3 (en) Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof
JP2004506405A5 (de)
WO2005014804A3 (en) Ubiquitin-specific protease
EP0854186A3 (de) Zellteilungs-Gen DivIB von Staphylococcus aureus
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
WO2001059152A3 (en) Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
Fawcett Use of Psychotropic Medications: Syndrome Diagnosis Versus Symptom Severity: Medications treat target symptoms, not the specific disorder.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition